Priaxon AG, based in Munich, Germany, discovers and develops small molecule therapeutics for novel target-ligand interactions. Proprietary, highly versatile chemo-informatics tools rapidly identify essential molecular determinants of novel target-ligand interactions, and apply this information to select suitable ligand motifs in previously unexplored chemical space.
Our company goal is to demonstrate the superior efficiency in terms of innovation, timelines and R&D economics of
applying Priaxon's tools to the rapid evaluation and NCE based exploitation of new drug targets.
Grant from Bavarian Research Foundation to Fund Research on PPI Inhibitors for Tumor Therapy read more
Cooperation with Munich Technical University Hospital to Develop Novel Anti-Infectives Extended read more
Lead Discovery Collaboration on Protein Protein Interaction Targets with Proteros read more